We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Two Lidoderm Class Action Deals Worth $271M Get Final OK

Law360, San Francisco (September 12, 2018, 10:54 PM EDT) -- A California federal judge on Wednesday approved “excellent” settlements ending claims that Teikoku, Endo and Actavis violated antitrust laws by stalling the release of a generic form of the Lidoderm pain patch, finalizing a $104.75 million deal with end payors and a $166 million deal with direct purchasers, including a combined $85.6 million in attorneys’ fees.

End payors included employee health and welfare benefit plans, unions or individuals who purchased the drug from third parties. Last month, their attorneys asked for $38.6 million in attorneys’ fees,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.